Latest Insider Transactions at Myriad Genetics Inc (MYGN)
This section provides a real-time view of insider transactions for Myriad Genetics Inc (MYGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MYRIAD GENETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MYRIAD GENETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,764
-2.58%
|
$47,640
$10.07 P/Share
|
|
Mar 15
2025
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,335
-1.75%
|
$33,350
$10.07 P/Share
|
|
Mar 15
2025
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
1,572
-1.18%
|
$15,720
$10.07 P/Share
|
|
Mar 15
2025
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-1.38%
|
$6,840
$10.07 P/Share
|
|
Mar 15
2025
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,118
-2.9%
|
$301,180
$10.07 P/Share
|
|
Mar 15
2025
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,729
-0.94%
|
$37,290
$10.07 P/Share
|
|
Mar 14
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,544
-4.41%
|
$85,440
$10.07 P/Share
|
|
Mar 14
2025
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,390
-2.25%
|
$43,900
$10.07 P/Share
|
|
Mar 14
2025
|
Shereen Solaiman Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,060
-5.18%
|
$60,600
$10.07 P/Share
|
|
Mar 14
2025
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
3,417
-2.51%
|
$34,170
$10.07 P/Share
|
|
Mar 14
2025
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
855
-1.69%
|
$8,550
$10.07 P/Share
|
|
Mar 14
2025
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,564
-3.49%
|
$375,640
$10.07 P/Share
|
|
Mar 14
2025
|
Samraat S. Raha Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,649
-1.56%
|
$76,490
$10.07 P/Share
|
|
Mar 14
2025
|
Scott J. Leffler Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,217
-2.77%
|
$62,170
$10.07 P/Share
|
|
Mar 14
2025
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,847
-1.46%
|
$58,470
$10.07 P/Share
|
|
Mar 13
2025
|
Jennifer Lynne Fox Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,145
+33.58%
|
-
|
|
Mar 13
2025
|
Dale Muzzey Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,773
+28.14%
|
-
|
|
Mar 13
2025
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,124
+21.69%
|
-
|
|
Mar 13
2025
|
Shereen Solaiman Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,145
+35.05%
|
-
|
|
Mar 13
2025
|
Margaret Ancona SVP, Chief of Staff |
BUY
Grant, award, or other acquisition
|
Direct |
54,124
+28.42%
|
-
|
|
Mar 13
2025
|
Natalie Munk Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+7.33%
|
-
|
|
Mar 13
2025
|
Samraat S. Raha Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
216,495
+30.69%
|
-
|
|
Mar 13
2025
|
Scott J. Leffler Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,165
+24.32%
|
-
|
|
Mar 13
2025
|
Mark Verratti Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,227
+19.83%
|
-
|
|
Mar 01
2025
|
Shereen Solaiman Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,912
-3.43%
|
$19,120
$10.73 P/Share
|
|
Feb 25
2025
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
2,697
-3.44%
|
$29,667
$11.74 P/Share
|
|
Feb 25
2025
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,016
-0.78%
|
$11,176
$11.74 P/Share
|
|
Feb 07
2025
|
Paul J Diaz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
114,828
+9.63%
|
-
|
|
Feb 07
2025
|
Mark Verratti Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,758
+4.05%
|
-
|
|
Feb 07
2025
|
Dale Muzzey Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,622
+8.27%
|
-
|
|
Feb 07
2025
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,758
+8.28%
|
-
|
|
Feb 07
2025
|
Margaret Ancona SVP, Chief of Staff |
BUY
Grant, award, or other acquisition
|
Direct |
6,468
+7.3%
|
-
|
|
Feb 07
2025
|
Natalie Munk Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,316
+6.65%
|
-
|
|
Jan 29
2025
|
Scott J. Leffler Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,230
-7.43%
|
$146,760
$12.54 P/Share
|
|
Jan 01
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
417
-0.39%
|
$5,421
$13.71 P/Share
|
|
Dec 11
2024
|
Samraat S. Raha Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,578
-9.79%
|
$414,092
$14.51 P/Share
|
|
Dec 10
2024
|
Mark Steven Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,816
+50.0%
|
-
|
|
Nov 30
2024
|
Samraat S. Raha Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,118
+0.37%
|
$14,534
$13.83 P/Share
|
|
Oct 11
2024
|
Paul J Diaz President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-1.53%
|
$330,000
$22.93 P/Share
|
|
Oct 09
2024
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,363
-1.41%
|
$200,712
$24.37 P/Share
|
|
Oct 09
2024
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,515
-1.9%
|
$60,360
$24.37 P/Share
|
|
Oct 09
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
452
-0.42%
|
$10,848
$24.37 P/Share
|
|
Sep 21
2024
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,075
-0.36%
|
$29,025
$27.64 P/Share
|
|
Sep 21
2024
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
964
-2.18%
|
$26,028
$27.64 P/Share
|
|
Sep 21
2024
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
966
-1.22%
|
$26,082
$27.64 P/Share
|
|
Sep 11
2024
|
Paul J Diaz President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-1.51%
|
$390,000
$26.72 P/Share
|
|
Sep 11
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,100
-1.91%
|
$54,600
$26.17 P/Share
|
|
Sep 09
2024
|
Heinrich Dreismann Director |
SELL
Open market or private sale
|
Direct |
10,000
-7.6%
|
$270,000
$27.05 P/Share
|
|
Sep 03
2024
|
Jennifer Lynne Fox Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,771
+50.0%
|
-
|
|
Sep 03
2024
|
Colleen F Reitan Director |
SELL
Open market or private sale
|
Direct |
46,012
-51.96%
|
$1,242,324
$27.95 P/Share
|